Scopus BioPharma Inc. (SCPS)
| Previous close | 0.0011 |
| Open | 0.0011 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1100 |
| Day's range | 0.0011 - 0.0011 |
| 52-week range | 0.0002 - 0.1050 |
| Volume | |
| Avg. volume | 1,281 |
| Market cap | 46,292 |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireScopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in model
- GlobeNewswire
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presentin
